1-9 of 9
Jason Konner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer

Available to Purchase
Angela K. Green, Qin Zhou, Alexia Iasonos, William A. Zammarrelli, III, Britta Weigelt, Lora H. Ellenson, Rashmi Chhetri-Long, Pooja Shah, Jade Loh, Vania Hom, Pier Selenica, Joseph Erinjeri, Iva Petkovska, Sarat Chandarlapaty, Seth Cohen, Rachel Grisham, Jason Konner, Maria M. Rubinstein, William Tew, Tiffany Troso-Sandoval, Carol Aghajanian, Vicky Makker
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (11): 2088–2096.
https://doi.org/10.1158/1078-0432.CCR-24-1999
Published: 03 June 2025
View articletitled, A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer
Open the PDF for A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets

Open Access
Claire F. Friedman, Vignesh Ravichandran, Kathryn Miller, Chad Vanderbilt, Qin Zhou, Alexia Iasonos, Malavika Vivek, Pamela Mishra, Mario M. Leitao, Jr, Vance Broach, Yukio Sonoda, Chrisann Kyi, Dmitriy Zamarin, Roisin E. O'Cearbhaill, Jason Konner, Michael F. Berger, Britta Weigelt, Amir Momeni Boroujeni, Kay J. Park, Carol Aghajanian, David B. Solit, Mark T.A. Donoghue
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4660–4668.
https://doi.org/10.1158/1078-0432.CCR-23-1078
Published: 14 November 2023
View articletitled, Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
Open the PDF for Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets in another window
Includes: Supplementary data
Journal Articles

Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes

Open Access
Kelly L. Bolton, Denise Chen, Rosario Corona de la Fuente, Zhuxuan Fu, Rajmohan Murali, Martin Köbel, Yanis Tazi, Julie M. Cunningham, Irenaeus C.C. Chan, Brian J. Wiley, Lea A. Moukarzel, Stacey J. Winham, Sebastian M. Armasu, Jenny Lester, Esther Elishaev, Angela Laslavic, Catherine J. Kennedy, Anna Piskorz, Magdalena Sekowska, Alison H. Brand, Yoke-Eng Chiew, Paul Pharoah, Kevin M. Elias, Ronny Drapkin, Michael Churchman, Charlie Gourley, Anna DeFazio, Beth Karlan, James D. Brenton, Britta Weigelt, Michael S. Anglesio, David Huntsman, Simon Gayther, Jason Konner, Francesmary Modugno, Kate Lawrenson, Ellen L. Goode, Elli Papaemmanuil
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4947–4956.
https://doi.org/10.1158/1078-0432.CCR-21-3817
Published: 14 November 2022
View articletitled, Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
Open the PDF for Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes in another window
Includes: Supplementary data
Journal Articles

Abstract AP27: A PHASE 2 STUDY OF TPIV200/HUFR-1 (A MULTI-EPITOPE FOLATE RECEPTOR ALPHA VACCINE) IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER

Free
Dmitriy Zamarin, Oladapo Yeku, Rosin E. O'Cearbhaill, Karen A. Cadoo, Jacqueline Gallagher, Sara Kravetz, Autumn McDonnell, Tiffany Troso-Sandoval, Paul Sabbatini, Stuart Lichtman, William Tew, Vicky Makker, Rachel N. Grisham, David M. Hyman, Carol Aghajanian, Jason Konner
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): AP27.
https://doi.org/10.1158/1557-3265.OVCASYMP18-AP27
Published: 15 November 2019
View articletitled, Abstract AP27: A PHASE 2 STUDY OF TPIV200/HUFR-1 (A MULTI-EPITOPE FOLATE RECEPTOR ALPHA VACCINE) IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER
Journal Articles

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine

Free
Ursula A. Matulonis, Michael J. Birrer, David M. O'Malley, Kathleen N. Moore, Jason Konner, Lucy Gilbert, Lainie P. Martin, Todd M. Bauer, Amit M. Oza, Karim Malek, Jan Pinkas, Stella K. Kim
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1727–1736.
https://doi.org/10.1158/1078-0432.CCR-18-2474
Published: 15 March 2019
View articletitled, Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine
Open the PDF for Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine in another window
Journal Articles

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

Free
Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, Lei Tian, Jane L. Meisel, Isaac García-Murillas, Charlotte Fribbens, Ros Cutts, Luciano G. Martelotto, Charlotte K.Y. Ng, Raymond S. Lim, Pier Selenica, Salvatore Piscuoglio, Carol Aghajanian, Larry Norton, Rajmohan Murali, David M. Hyman, Laetitia Borsu, Maria E. Arcila, Jason Konner, Jorge S. Reis-Filho, Roger A. Greenberg, Mark E. Robson, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (21): 6708–6720.
https://doi.org/10.1158/1078-0432.CCR-17-0544
Published: 31 October 2017
View articletitled, Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Open the PDF for Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

Free
Paul Sabbatini, Takemasa Tsuji, Luis Ferran, Erika Ritter, Christine Sedrak, Kevin Tuballes, Achim A. Jungbluth, Gerd Ritter, Carol Aghajanian, Katherine Bell-McGuinn, Martee L. Hensley, Jason Konner, William Tew, David R. Spriggs, Eric W. Hoffman, Ralph Venhaus, Linda Pan, Andres M. Salazar, Catherine Magid Diefenbach, Lloyd J. Old, Sacha Gnjatic
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (23): 6497–6508.
https://doi.org/10.1158/1078-0432.CCR-12-2189
Published: 29 November 2012
View articletitled, Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Open the PDF for Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Pemetrexed Plus Gemcitabine Given Biweekly with B-Vitamin Support in Solid Tumor Malignancies or Advanced Epithelial Ovarian Cancer

Free
Martee L. Hensley, Joseph Larkin, Matthew Fury, Scott Gerst, D. Fritz Tai, Paul Sabbatini, Jason Konner, Mauro Orlando, Tiana L. Goss, Carol A. Aghajanian
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 6310–6316.
https://doi.org/10.1158/1078-0432.CCR-08-0338
Published: 30 September 2008
View articletitled, A Phase I Trial of Pemetrexed Plus Gemcitabine Given Biweekly with B-Vitamin Support in Solid Tumor Malignancies or Advanced Epithelial Ovarian Cancer
Open the PDF for A Phase I Trial of Pemetrexed Plus Gemcitabine Given Biweekly with B-Vitamin Support in Solid Tumor Malignancies or Advanced Epithelial Ovarian Cancer in another window
Journal Articles

Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Free
Paul J. Sabbatini, Govind Ragupathi, Chandra Hood, Carol A. Aghajanian, Margrit Juretzka, Alexia Iasonos, Martee L. Hensley, Maria K. Spassova, Ouathek Ouerfelli, David R. Spriggs, William P. Tew, Jason Konner, Henrik Clausen, Nadeem Abu Rustum, Samuel J. Dansihefsky, Philip O. Livingston
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (14): 4170–4177.
https://doi.org/10.1158/1078-0432.CCR-06-2949
Published: 18 July 2007
View articletitled, Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Open the PDF for Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in another window